다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
캐나다
TSX
Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc (EPRX) 뉴스

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:TSX:EPRX

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/20	21:00	PR Newswire (Canada)	Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/20	21:00	PR Newswire (US)	Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/15	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/15	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/14	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/14	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/13	07:56	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/13	07:56	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	07:00	PR Newswire (US)	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/08	07:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/01	08:36	PR Newswire (US)	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/11/01	08:36	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/28	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/28	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/15	20:00	PR Newswire (US)	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/15	20:00	PR Newswire (Canada)	Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/10	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/10	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/03	06:01	PR Newswire (Canada)	Eupraxia Pharmaceuticals Strengthens Senior Management Team	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/10/03	06:01	PR Newswire (US)	Eupraxia Pharmaceuticals Strengthens Senior Management Team	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/20	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/20	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/11	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/11	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/04	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/09/04	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/08/08	06:00	PR Newswire (US)	Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/08/08	06:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/08/02	20:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility	TSX:EPRX	Eupraxia Pharmaceuticals Inc
2024/08/02	20:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility	TSX:EPRX	Eupraxia Pharmaceuticals Inc

검색 관련기사 보기:TSX:EPRX

1 2 3 4 5 다음 >>

Energy Select Sector SPDR

Deutsche Telekom (QX)

US Dollar vs Yen

Gold vs US Dollar

JP Morgan Chase

Health Care Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관